Sun Pharma Advanced Research Company share news and announcements
NSE: SPARCBSE: 532872Pharmaceuticals & BiotechnologySmall Cap
Last close ₹171.77down ₹1.32 (0.76%)BSE ₹171.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹173.09.
52-week range of traded prices to 23 Oct 2026
₹108.00Low, 23 Mar 2026₹289.00High, 8 Jul 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹5,574 Cr778th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 3.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 18 May 2026
- 4.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 10 Aug 2026
- 118.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 84.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 18 May 2026
- 0.42
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,97,11238.6% delivered
Sun Pharma Advanced Research Company board meetings
123 filed, newest first. Page 3 of 3.
Jul 2012
20 Jul · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the first quarter ended June 30, 2012.
Apr 2012
17 Apr · Board meeting
Interalia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2012.
Jan 2012
19 Jan · Board meeting
Interalia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter ended December 31, 2011.
Oct 2011
12 Oct · Board meeting
Interalia, to consider and take on record the Financial Results of the Company for the second quarter/ half year ended September 30, 2011.
Jul 2011
29 Jul · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the first quarter ended June 30, 2011.14 Jul · Board meeting
Committee of the Board of Directors has, vide its resolution passed in the meeting held on July 14, 2011 authorized the further issuance of equity shares of Re. 1 each of the Company, on rights basis to the shareholders of the Company on such ratio and at such price and premium as may be decided in consultation with the Lead Managers to the proposed rights issue, so that the funds raised by way of right issue of shares is not more than Rs.200 crores. The ratio of rights share entitlements, the issue price and the record date for fixing the entitlement of shareholders to such rights issue shall be informed in due course when decided.11 Jul · Board meeting
To consider in principle, the issue of equity shares of Re.1 each of the Company by way of rights issue for raising the funds for the Company. Further the Company has informed the Exchange that as per the agenda of the Committee Meeting, however the Committee shall not decide at the said meeting about the ratio of rights share entitlements, the issue price and the record date for fixing the rights entitlement of shareholders & which shall be decided in due course .
Apr 2011
26 Apr · Board meeting
Interalia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2011.
Jan 2011
18 Jan · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the third quarter / nine months ended December 31, 2010.
Oct 2010
12 Oct · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the second quarter ended September 30, 2010.
Jul 2010
9 Jul · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the first quarter ended June 30, 2010.
May 2010
7 May · Board meeting
To consider and approve the audited financial results of the company for the year ended March 31, 2010.
Jan 2010
11 Jan · Board meeting
Meeting on 23 Jan 2010: “Unaudited Financial Results for the qtr ended Dec 31, 2009”
Oct 2009
9 Oct · Board meeting
Meeting on 24 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Jul 2009
7 Jul · Board meeting
Meeting on 20 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”
May 2009
12 May · Board meeting
Interalia, to consider the audited financial results of the Company for the year ended March 31, 2009.
Jan 2009
13 Jan · Board meeting
Meeting on 24 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Oct 2008
15 Oct · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the half year / second quarter ended September 30, 2008.
Jul 2008
14 Jul · Board meeting
Meeting on 29 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”
Apr 2008
28 Apr · Board meeting
Interalia, to consider the audited financial results of the Company for the year ended March 31, 2008.
Jan 2008
8 Jan · Board meeting
Meeting on 24 Jan 2008: “Unaudited Financial Results for the qtr ended Dec 31, 2007”
Oct 2007
9 Oct · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the half year / second quarter ended September 30, 2007.
Jul 2007
18 Jul · Board meeting
Meeting on 23 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”